Transit Passes for People with HIV

N/A

Waitlist Available

Led By Jay Orne, PhD

Research Sponsored by The Aliveness Project

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Inability to communicate in English

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if giving people living with HIV and unstable housing an unlimited transit pass will help improve their health. Researchers want to know if those who receive the pass manage their HIV better and use

Who is the study for?

This trial is for people living with HIV who don't have stable housing. Participants should be willing to complete surveys and allow access to their HIV lab tests. There are no specific exclusion criteria provided, but typically participants would need to meet certain health standards.

What is being tested?

The study is testing whether giving out unlimited transit passes can help improve the management of HIV and increase the use of social services among unstably housed individuals. It compares a group with these passes against one without, over six months.

What are the potential side effects?

Since this trial involves providing transportation assistance rather than a medical intervention, there are no direct side effects from drugs or treatments. However, changes in lifestyle or stress levels due to increased mobility could indirectly affect participants.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot communicate in English.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Participants with HIV Viral Suppression

Number of Participants with an HIV related Medical Visit

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention GroupExperimental Treatment1 Intervention

The intervention group will be provided a transit pass for the Minneapolis Metro transit system that will be paid for by the study for 6 months.

Group II: ControlActive Control1 Intervention

The control group will receive the current standard of care, in which people are eligible to receive up to two $10 bus cards from their case manager per month.

0 / 1Eligibility criteria met